Att 2_60d FRN

76592

Federal Register / Vol. 81, No. 213 / Thursday, November 3, 2016 / Notices

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

mstockstill on DSK3G9T082PROD with NOTICES

Advisory Committee on Breast Cancer
in Young Women (ACBCYW)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 1:00 p.m.–5:00 p.m.
EST, December 13, 2016.
Place: This meeting will be held via
Teleconference and web access.
Teleconference and web access login
information is as follows:
Toll-Free Telephone: 1–888–566–
6510, Participant passcode: 3895011.
Net Conference and Web Url: https://
www.mymeetings.com/nc/join/.
Conference number: PWXW1545545,
Audience passcode: 3895011.
Participants can join the event
directly at: https://
www.mymeetings.com/nc/join.php?
i=PWXW1545545&p=3895011&t=c.
WebEx Required Download:
Participants must have the WebEx Event
Manager installed prior to joining the
web portion of the meeting.
Status: Open to the public, limited
only by the audio phone lines and net
conference access available.
Purpose: The committee provides
advice and guidance to the Secretary,
HHS; the Assistant Secretary for Health;
and the Director, CDC, regarding the
formative research, development,
implementation and evaluation of
evidence-based activities designed to
prevent breast cancer (particularly
among those at heightened risk) and
promote the early detection and support
of young women who develop the
disease. The advice provided by the
Committee will assist in ensuring
scientific quality, timeliness, utility, and
dissemination of credible appropriate
messages and resource materials.
Matters for Discussion: The agenda
will include discussions on the current
and emerging topics related to breast
cancer in young women. These will
include public health communication,
breast cancer in young women digital
and social media campaigns, and CDC
updates. Committee workgroups will
report findings to the committee.
Agenda items are subject to change as
priorities dictate.
Online Registration Required: All
ACBCYW Meeting participants must
register for the meeting online at least 3
business days in advance at http://

VerDate Sep<11>2014

17:54 Nov 02, 2016

Jkt 241001

www.cdc.gov/cancer/breast/what_cdc_
is_doing/meetings.htm. Please complete
all the required fields before submitting
your registration and submit no later
than December 8, 2016.
Contact Person for More Information:
Temeika L. Fairley, Ph.D., Designated
Federal Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 5770 Buford Hwy, NE.,
Mailstop K52, Atlanta, Georgia 30341,
Telephone (770) 488–4518, Fax (770)
488–4760. Email: acbcyw@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–26569 Filed 11–2–16; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–17–17BZ]; Docket No. CDC–2016–
0104]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project entitled ‘‘Project
Pride.’’ This project is funded by CDC
at 12 health departments in the United
States. The health departments will
report standardized program monitoring
and evaluation (M&E) data to CDC. CDC
is requesting approval to collect
standardized HIV prevention program
evaluation data from funded health
departments.

SUMMARY:

PO 00000

Frm 00040

Fmt 4703

Sfmt 4703

Written comments must be
received on or before January 3, 2017.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2017–
0104 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 3501–3520),
Federal agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor. In
addition, the PRA also requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each new proposed
collection, each proposed extension of
existing collection of information, and
each reinstatement of previously
approved information collection before
submitting the collection to OMB for
approval. To comply with this
requirement, we are publishing this
notice of a proposed data collection as
described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
DATES:

E:\FR\FM\03NON1.SGM

03NON1

76593

Federal Register / Vol. 81, No. 213 / Thursday, November 3, 2016 / Notices
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Project PrIDE—New—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
State, local and territorial health
departments in the U.S. are
implementing high impact HIV
prevention programs to reduce new HIV
infections among populations of gay,
bisexual, and other men who have sex
with men (MSM) and transgender
persons. Additional effort is needed to
realize the benefits of new prevention
strategies that have the potential to
significantly reduce new HIV infections
and increase viral suppression among
MSM and transgender persons.
Pre-exposure prophylaxis (PrEP) is a
potent new prevention tool for MSM

without HIV but who are at substantial
risk of acquiring HIV infection. The
daily use of oral, antiretroviral
medication (PrEP) with co-formulated
tenofovir disoproxil fumarate and
emtricitabine (marketed as Truvada®) is
proven to significantly reduce the risk of
HIV acquisition among sexually active
adults. In July 2012, the US Food and
Drug Administration approved an HIV
prevention indication for Truvada, and
in May 2014 CDC published Public
Health Service clinical practice
guidelines for provision of PrEP to
persons at substantial risk of HIV
acquisition through sexual or injection
routes of transmission as part of a
package of HIV prevention clinical
services. It is critical for health
departments to address barriers to and
facilitate broader awareness, support
and capacity for the scale-up of PrEP
services for MSM and transgender
persons at high risk for HIV infection,
particularly persons of color,
recognizing that the population with the
highest incidence of HIV in the U.S. is
young African American MSM.
Another potent prevention tool
involves antiretroviral medication to
suppress HIV–1 viral load, improve
health outcomes and reduce
transmission risk among people living
with HIV (PLWH). The importance of
antiretroviral treatment has increased
focus on interventions and public health
strategies designed to link, engage and
re-engage persons living with HIV in
health care, with the ultimate outcome
of suppressing HIV viral load,
decreasing morbidity and increasing
survival. To increase viral suppression,
more people who are diagnosed with
HIV will need to be retained in HIV
medical care and receive antiretroviral
treatment. There is a need for health
departments to implement public health
strategies for improving linkage,
engagement and re-engagement of MSM

and transgender persons who are not in
care.
Data to Care is a public health strategy
for identifying these individuals. Data to
Care is based on the use of surveillance
data to intervene directly in disease
control. Data to Care programs use
laboratory reports received by a health
department’s HIV surveillance program,
and a range of other data sources as
markers of HIV care, and analyze these
reports to confidentially identify HIVdiagnosed individuals who are not
engaged in HIV medical care or have not
achieved viral suppression. Several state
health departments have taken steps
toward initiating a Data to Care
program, and a few have reported
successful implementation of Data to
Care activities. It is important that these
efforts be expanded and that other state,
local and territorial health departments
scale up and implement this promising
public health strategy to improve
outcomes along the HIV continuum of
care and prevent new HIV infections.
The purpose of this project is to
support 12 health departments in the
United States to implement PrEP and
Data to Care demonstration projects for
200 clients annually, prioritizing MSM
and transgender persons at high risk of
HIV infection, particularly persons of
color.
Health departments that are involved
in this project will be required to
prioritize their services to these
populations. Services may also be
provided for persons at substantial risk
for HIV (for PrEP) or persons who have
HIV and are not virally suppressed or
have ongoing risk behavior (for Data to
Care) who are not MSM or transgender.
CDC HIV program grantees will
collect, enter or upload, and report
budget data, information on the HIV
prevention and care services, and client
demographic characteristics with an
estimated of 1,104 burden hours.

mstockstill on DSK3G9T082PROD with NOTICES

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Number of
responses per
respondent

Average burden
per response
(in hours)

Total burden
hours

Type of respondents

Form name

Clients ...........................................
Health Departments ......................
Health Departments ......................

Data Elements ..............................
Data Management ........................
Performance Progress Report .....

2,400
12
12

1
2
1

25/60
20/60
8

1,000
8
96

Total .......................................

.......................................................

..........................

..........................

..........................

1,104

VerDate Sep<11>2014

17:54 Nov 02, 2016

Jkt 241001

PO 00000

Frm 00041

Fmt 4703

Sfmt 4703

E:\FR\FM\03NON1.SGM

03NON1

76594

Federal Register / Vol. 81, No. 213 / Thursday, November 3, 2016 / Notices

Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–26500 Filed 11–2–16; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

mstockstill on DSK3G9T082PROD with NOTICES

Advisory Board on Radiation and
Worker Health (ABRWH or Advisory
Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the
aforementioned committee:
Times and Dates: 8:15 a.m.–5:00 p.m.,
Mountain Time, November 30, 2016;
8:15 a.m.–10:00 a.m., Mountain Time,
December 1, 2016.
Public Comment Time and Date: 5:00
p.m.–6:00 p.m.*, Mountain Time,
November 30, 2016.
* Please note that the public comment
period may end before the time
indicated, following the last call for
comments. Members of the public who
wish to provide public comments
should plan to attend the public
comment session at the start time listed.
Place: Hilton Santa Fe Historic Plaza,
100 Sandoval Street, Santa Fe, New
Mexico 87501; Phone: (505) 986–6416;
Fax: (505) 986–6439.
Status: Open to the public, limited
only by the space available. The meeting
space accommodates approximately 100
people. The public is also welcome to
listen to the meeting by joining the
teleconference at USA toll-free, dial-in
number, 1–866–659–0537 and the pass
code is 9933701.
Live Meeting Connection: https://
www.livemeeting.com/cc/cdc/join?id=
Z9K2DF&role=attend&pw=ABRWH;
Meeting ID: Z9K2DF; Entry Code:
ABRWH.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include

VerDate Sep<11>2014

17:54 Nov 02, 2016

Jkt 241001

providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule, advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule, advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program, and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
intervals, rechartered on March 22, 2016
pursuant to Executive Order 13708, and
will expire on September 30, 2017.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters for Discussion: The agenda for
the Advisory Board meeting includes:
NIOSH Program Update; Department of
Labor Program Update; Department of
Energy Program Update; Dose
Reconstruction Report to the Secretary;
SEC Petitions Update; Site Profile
review for Hooker Electrochemical
(Niagara, New York); SEC petitions for:
Area IV of Santa Susana Field
Laboratory (1965–1988; Ventura County,
California), Carborundum Company
(1943–1976; Niagara Falls, New York),
Savannah River Site (1973–2007; Aiken,
South Carolina), and Los Alamos
National Laboratory (1996–2005; Los
Alamos, New Mexico); and Board Work
Sessions.
The agenda is subject to change as
priorities dictate.
In the event an individual cannot
attend, written comments may be
submitted to the contact person below
well in advance of the meeting. Any
written comments received will be
provided at the meeting in accordance

PO 00000

Frm 00042

Fmt 4703

Sfmt 4703

with the redaction policy provided
below.
Policy on Redaction of Board Meeting
Transcripts (Public Comment):
(1) If a person making a comment
gives his or her personal information, no
attempt will be made to redact the
name; however, NIOSH will redact
other personally identifiable
information, such as contact
information, social security numbers,
case numbers, etc., of the commenter.
(2) If an individual in making a
statement reveals personal information
(e.g., medical or employment
information) about themselves that
information will not usually be
redacted. The NIOSH Freedom of
Information Act (FOIA) coordinator
will, however, review such revelations
in accordance with the Federal
Advisory Committee Act and if deemed
appropriate, will redact such
information.
(3) If a commenter reveals personal
information concerning a living third
party, that information will be reviewed
by the NIOSH FOIA coordinator, and
upon determination, if deemed
appropriated, such information will be
redacted, unless the disclosure is made
by the third party’s authorized
representative under the Energy
Employees Occupational Illness
Compensation Program Act (EEOICPA)
program.
(4) In general, information concerning
a deceased third party may be disclosed;
however, such information will be
redacted if (a) the disclosure is made by
an individual other than the survivor
claimant, a parent, spouse, or child, or
the authorized representative of the
deceased third party; (b) if it is unclear
whether the third party is living or
deceased; or (c) the information is
unrelated or irrelevant to the purpose of
the disclosure.
The Board will take reasonable steps
to ensure that individuals making
public comment are aware of the fact
that their comments (including their
name, if provided) will appear in a
transcript of the meeting posted on a
public Web site. Such reasonable steps
include: (a) A statement read at the start
of each public comment period stating
that transcripts will be posted and
names of speakers will not be redacted;
(b) A printed copy of the statement
mentioned in (a) above will be
displayed on the table where
individuals sign up to make public
comments; (c) A statement such as
outlined in (a) above will also appear
with the agenda for a Board Meeting
when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above
will appear in the Federal Register

E:\FR\FM\03NON1.SGM

03NON1